A1: Clinical Inactive Disease in the Pediatric Rheumatology Care and Outcomes Improvement Network Cohort: Which Components of Clinical Inactive Disease Do Patients Not Achieve?
A2: Rapid and Sustained Response in Patients Suffering From Severe Cryopyrin-Associated Periodic Syndromes Treated With Anakinra (Kineret®)
A3: Efficacy and Safety of Adalimumab in Pediatric Patients With Enthesitis Related Arthritis
A4: Efficacy and Safety of Tocilizumab in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data From CHERISH
A5: Detectable Anti-Infliximab Antibodies in Children Treated with Infliximab for Rheumatic Diseases
A6: Tapering and Withdrawal of Tocilizumab in Patients With Systemic Juvenile Idiopathic Arthritis in Inactive Disease: Results From an Alternative Dosing Regimen in the TENDER Study
A7: Initial Assessment of Multi-biomarker Disease Activity Assay in JIA
A8: Juvenile Idiopathic Arthritis with Dry Synovitis: Clinical and Imaging Aspects in a Cohort of 10 Patients
A9: Exploring Systemic Lupus Erythematosus from the Molecular Level and Dissecting the Disease Mechanism by Molecular Imaging
A10: Younger Age and Severity of Renal Presentation Distinguishes Microscopic Polyangiitis From Granulomatosis With Polyangiitis in Children: An ARChiVe Study
A11: Assessment of Radiographic Progression in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Data From CHERISH
A12: The Role of Serum S100A12 Protein Levels in Disease Flare After Withdrawal of Anti-tumor Necrosis Factor Therapy in Polyarticular Forms of Juvenile Idiopathic Arthritis
A13: The Research in Arthritis in Canadian Children Emphasizing Outcomes (ReACCh Out) Cohort: Prospective Determination of the Incidence of New Onset Uveitis in Juvenile Idiopathic Arthritis
A14: Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Systemic Juvenile Idiopathic Arthritis
A15: Predicting Macrophage Activation Syndrome in Pediatric Systemic Lupus Erythematosus Patients at Diagnosis
A16: Long-term follow-up of 36 Pediatric Antiphospholipid Syndrome Patients: A Retrospective Study
A17: A Prospective Study Comparing Infectious Risks, Disease Activity, and Cytokine Alterations in Children with Juvenile Idiopathic Arthritis Treated with and without Tumor Necrosis Factor-alpha Inhibitors
A18: Risk Factors for Symptomatic Avascular Necrosis in Childhood-Onset Systemic Lupus Erythematous
A19: Rituximab Therapy has a Rapid and Durable Response for Refractory Cytopenia in Childhood-Onset Systemic Lupus Erythematosus
A20: Understanding the Use and Biology of TNF Therapy in JIA—Clinical Outcomes
A21: Physical Activity in Children with Juvenile Idiopathic Arthritis (JIA): The LEAP (Linking Exercise, Activity, and Pathophysiology in Childhood Arthritis) Study
A22: Consensus Treatment Plans for Induction Therapy in Childhood Proliferative Lupus Nephritis—Status of Use in Daily Clinical Care
A23: Favorable Response to Belimumab in Childhood-Onset Systemic Lupus Erythematosus
A24: Validation of BASDAI and BASFI in Children with Spondyloarthritis
A25: The Association of Immunogenetic and Environmental Factors with Disease Course in Patients with Juvenile Idiopathic Inflammatory Myopathies
A26: Longitudinal Disease Trajectory of Juvenile Dermatomyositis
A27: Polyomavirus Excretion in Children with Rheumatic Diseases on Immunosuppressive Therapy
A28: Description of the Juvenile Localized Scleroderma Subgroup of the CARRA Registry
A29: Power and Colour Doppler Findings in Lower Extremity Entheses of Healthy Children—Effect of Measurement Distance from Insertion and Joint Position
A30: Assessment of Construct and Discriminative Validity of the 3-Variable JADAS in Relation of Parent-Reported Outcomes
A31: Vitamin D Status is a Determinant of the Effect of Atorvastatin on Carotid Intima Medial Thickening Progression Rate in Children with Lupus: An Atherosclerosis Prevention in Pediatric Lupus Erythematosus Substudy
A32: Low Vitamin D Status is Associated with Avascular Necrosis: An Atherosclerosis Prevention in Pediatric Lupus Erythematosus Substudy
A33: Cognitive Performance Scores for the Pediatric Automated Neuropsychological Assessment Metrics in Childhood-Onset Systemic Lupus Erythematosus
A34: Seeing the Forest Through the Trees: Predictors of Inflammatory Causes of Joint Pain in New Patients
A35: Differential Benefit of Temporomandibular Joint Steroid Injections by Juvenile Idiopathic Arthritis Subtype
A36: Long-term Pharmacokinetics of Body Surface Area-Adjusted Doses of Golimumab Following Repeated Subcutaneous Administrations in Pediatric Patients With Polyarticular Juvenile Idiopathic Arthritis
A37: Children with Small Joint Oligoarticular Onset Juvenile Idiopathic Arthritis Are More Likely to Develop Extended Arthritis
A38: Twelve Years' Experience with Etanercept in the Treatment of Juvenile Idiopathic Arthritis: How It Has Changed Practice—The German Biologics JIA Registry (BiKeR)
A39: Efficacy and Safety of Methotrexate in Oligoarticular Persistent Juvenile Idiopathic Arthritis
A40: Periodic Fever Syndromes in Canada: Results from a National Surveillance Program
A41: The Effects of Youngsters' Eyesight on Quality of Life as a Measure of Uveitis Activity, Visual Function and Vision Related Quality of Life in Childhood Uveitis
A42: Anti-Ro and Anti-La Antibodies in the General Pregnant Population: Rates and Fetal Outcomes
A43: Juvenile Idiopathic Arthritis in Relation to Maternal Prenatal Smoking
A44: High Levels of DEK Autoantibodies May Predict Early Flare Following Cessation of Anti-TNF Therapy
A45: Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis
A46: Analysis of Factors Associated With Good Response to Intra-articular Injections in Patients With Juvenile Idiopathic Arthritis
A47: Progress Report on the Development of New Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies
A48: Durometer Measures Discriminate Affected versus Normal Skin in Pediatric Localized Scleroderma
A49: Intra-Articular Corticosteroids Injections in the Lower Extremities: How Do Ankles Respond?
A50: Mental Health and Healthcare Utilization in Children with SLE and MCTD
A51: C1q Deficiency and Autoimmunity—A Single Centre Experience
A52: The Impact of Adalimumab on Growth in Patients With Juvenile Idiopathic Arthritis
A53: Natural History of Pediatric Class V Membranous Lupus Nephritis—A Serial Biopsy Study
A54: Insulin Sensitivity Is Improved in sJIA Children With Insulin Resistance After Tocilizumab Treatment: Results From the TENDER Study
A55: Clostridium difficile Infection-Associated Reactive Arthritis in a Pediatric Cohort
A56: Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab
A57: Four Prolonged Cases of Eosinophilic Fasciitis in Children
A58: Demographics, Clinical Features and Therapies of Patients with Juvenile Dermatomyositis Participating in a National Myositis Patient Registry
A59: Dexamethazone Therapy for Septic Arthritis in Children: a Follow Up Study
A60: Optic Nerve and Retinal Features in Uveitis Associated With Juvenile Systemic Granulomatous Disease (Blau Syndrome)
A61: Prevalence of Streptococcal Antibodies in Pediatric Non-Rheumatic Fever Syndromes in Areas of Low Rheumatic Fever Incidence
A62: GO-KIDS Imaging Substudy: MRI Treatment Response to 30 mg/m2 Q4W Subcutaneous (SC) Injections of Golimumab (GLM) and Placebo in Children With Polyarticular JIA (pJIA)—Preliminary Results of the Placebo Controlled Portion (Week 48)
A63: Treatment of Arthritis in Animal Models of the Mucopolysaccharidoses Using a Novel Anti-Inflammatory Drug, Pentosan Polysulfate
A64: Patient-Reported Side Effects with Weekly Injections of Methotrexate in Tertiary Care Rheumatology Clinic
A65: Procedural Pain with Weekly Injections of Subcutaneous Methotrexate in Children with Rheumatic Disorders
A66: Assessment of Radiographic Progression in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Results From the TENDER Trial
A67: Factors That Contribute to Classification of Children as Having Undifferentiated Juvenile Idiopathic Arthritis
A68: The Role of Serum S100A12 Protein Levels in Maintaining Inactive Disease on Anti-tumor Necrosis Factor Therapy in Polyarticular Forms of Juvenile Idiopathic Arthritis
A69: Lupus Nephritis and Autoantibody Characteristics of a Single Center Cohort of Male Pediatric SLE Patients
A70: Medication Use in the Treatment of Juvenile Idiopathic Uveitis Patients Enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry
A71: Localized Myositis as a Manifestation of Systemic-Onset Juvenile Idiopathic Arthritis: A Case Series From a Tertiary-Care Hospital
A72: Predicting Progression From Oligoarticular to Polyarticular Juvenile Arthritis
A73: A Comparison of Serologic Profiles of Children With Sjögren Syndrome Based on the Presence or Absence of Parotitis
A74: Nutritional and Metabolic Assessment in Girls With Systemic Lupus Erythematosus
A75: Proposal of the Bristol Criteria for the Diagnosis of Chronic Non-bacterial Osteitis From a Cohort of 41 Patients
A76: Long-Term Efficacy of Canakinumab in Childhood Colchicine Resistant Familial Mediterranean Fever
A77: Clinical and Laboratory Features and Systemic Lupus Erythematous Disease Activity Index 2000 (SLEDAI 2K) at Onset and Follow Up in a Cohort of 109 Paediatric Lupus Patients From a Tertiary Level Centre in India
A78: Urine Biomarkers Role in Predicting the Future Development of Renal Functional Loss With Lupus Nephritis in Children and Adults
A79: Pulmonary Hemorrhage in Pediatric Systemic Lupus Erythematous: Clinical Course and Outcomes
A80: Skeletal Features of Neonatal-Onset Multisystem Inflammatory Disease (NOMID) on Anakinra Treatment: Long-Term Follow-up
A81: Spectrum of Mevalonate Kinase Deficiency: Is Colitis More Common Than We Think?
A82: Lyme Arthritis: an Emerging Clinical Problem in Nova Scotia, Canada
A83: Power Doppler Visualization of Epiphyseal and Growth Plate Vascularity in Affected and Contralateral Unaffected Joints in Patients with Juvenile Idiopathic Arthritis
A84: Changes over Time in Symptoms and Treatment of Juvenile Primary Fibromyalgia Syndrome
A85: Effect of Childhood-Onset Systemic Lupus Erythematosus on Linear Height and Body Mass Index
A86: Total Body MRI, A Guide to Diagnosis in Patients With Osteo-Articular Pain and Inflammation
A87: Different Tocilizumab Therapeutic Protocols and Possibility Achieving Tocilizumab-Off Remission in Systemic Juvenile Idiopathic Arthritis
A88: Tocilizumab: A Practical Experience From a North Indian Centre
A89: The Relationship Between Benign Joint Hypermobility Syndrome and Developmental Coordination Disorders in Children
A90: Pediatric Henoch-NSchöAdonlein Purpura: Can Length of Hospital Stay Be Predicted?
A91: The Development and Initial Evaluation of a Standardised Play Based Hand Assessment Tool for Use in Children and Adolescents: the PizzaPutty™ Test
A92: Intensive Physical Therapy With Desensitization in Collaboration with Psychological Care Is a Successful Outpatient Treatment for Amplified Musculoskeletal Pain Syndrome
A93: Childhood Granulomatosis With Polyangiitis: Standardized Disease Assessment in 6 Czech Children
A94: Examination of Resiliency, Pain, Coping and Quality of Life in Children with Rheumatologic Disease
A95: The Risk of Dyslipidemia in Pediatric Arthritis Patients Is Similar to That of Adult Patients With Arthritis
A96: The Roller Coaster of Juvenile Idiopathic Arthritis: A Qualitative Examination of Parents' Emotional Responses to the Disease and Its Management
A97: Endothelial Function in Children With a History of Henoch-Schonlein Purpura
A98: Rescue Treatment by Increased Doses of IL-1 Inhibitors for Macrophage Activation Syndrome in Children With Systemic Juvenile Idiopathic Arthritis
A99: Symptom and Treatment Characteristics of Juvenile Primary Fibromyalgia Syndrome in the CARRA Registry: Are Males and Females Created Equal?
A100: Predictors of Involvement in Leisure Activities Among Children and Youth With Juvenile Idiopathic Arthritis
A101: The Impact of Sleep and Cytokine Levels on Pain Perception in JIA
A102: Acceptability and Practicality of the Paediatric Gait, Arms, Legs and Spine Examination in Detecting Musculoskeletal Abnormalities in Peruvian Children
A103: Childhood Onset Takayasu Arteritis—Experience From a Tertiary Care Centre in South India
A104: Aggressive Erosive Synovitis in Juvenile Idiopathic Arthritis
A105: Late Cardiac Assessment in Children Who Were Diagnosed With Post Streptococcal Reactive Arthritis—A Long Term Study
A106: Rituximab Use in Pediatric Antiphospholipid Antibody Positive Patients
A107: Dream Doctors—Medical Clowns Increase the Effect of Nitrous Oxide Sedation in Intra-Articular Corticosteroid Injection for Juvenile Idiopathic Arthritis
A108: Linking Exercise, Activity and Pathophysiology in Childhood Arthritis: An Innovative Canadian Knowledge Translation Strategy
A109: Insufficient CARRA Registry Data Available to Adequately Evaluate for Associations Between Juvenile Idiopathic Arthritis, Antibody Status, and Smoke Exposure
A110: The Impact of Shoe Wear on the 6 Minute Walk Test in Adolescents with Juvenile Idiopathic Arthritis
A111-a: Setting Up of Japanese Online Registry of Pediatric Rheumatic Disease
A111-b: Evaluation of an NHS Juvenile Idiopathic Arthritis (JIA) Treatment Pathway Compared to Published International Recommendations
A112: Prevention of Late Stage Renal Failure in BXSB SLE Mouse Model with Human Bone Marrow Derived Mesenchymal Stem Cell Treatment
A113: TCR-independent Activation of T-cells Through CD31 Triggering as an Etiology of Cytokine Production in Juvenile Idiopathic Arthritis
A114: Methylprednisolone-Induced Inhibition of miR-155 Expression Increases SOCS1-Driven Suppression of Cytokine Signaling
A115: Deep Immunophenotyping in the Identification of Clinically Meaningful Immune Signatures in Juvenile Idiopathic Arthritis
A116: Increased Antibody Responses to Porphyromonas Gingivalis in Children With Anticyclic Citrullinated Peptide Antibody-Positive Juvenile Idiopathic Arthritis
A117: Demonstration of Antibodies to Multiple Citrullinated Epitopes in the Sera of Patients With Juvenile Idiopathic Arthritis
A118: Laboratory Investigation of the Role of Toll-Like Receptors on Kidney Cells in Pathogenesis of Lupus Nephritis
A119: Deep Sequencing Analysis of the T Regulatory and T Effector Repertoire in Juvenile Idiopathic Arthritis
A120: Familial Autoimmunity in the CARRA Registry
A121: In Search of Infectious Triggers of Periodic Fever, Aphthous Stomatitis, Pharyngitis and Adenitis Syndrome
A122: Metabolomic Analysis of Breath Volatile Organic Compounds Reveals Unique Breathprints in Children With Juvenile Idiopathic Arthritis
A123: HLA Associations in a Matched Cohort of Juvenile Idiopathic Arthritis Children With and Without Uveitis
A124: Hepcidin as a Predictor of Evolution of Anemia of Chronic Disease to a Macrophage Activation Syndrome in Children With Juvenile Idiopathic Arthritis
A125: Immunomodulatory Factors Produced by Mesenchymal Stem Cells After in vitro Priming with Danger Signals
A126: Clusters of Autoimmune Diseases in Children and the Role of PTPN22 C1858T Gene Polymorphism in Pediatric Polyautoimmunity
A127: Validating Popliteal Lymph Node Phenotype and Bin Expansion as Biomarkers of Rheumatoid Arthritis Knee Flare in Clinical Pilot Studies
A128: Hierarchical Clustering Methodology for Exploration of Proteomic Profile in Tears: Seeking for Markers of Uveitis Associated With Juvenile Idiopathic Arthritis
A129: Unlike Fibroblast-like Synoviocytes from Oligoarticular Juvenile Idiopathic Arthritis, Fibroblast-like Synoviocytes From Polyarticular Subtype Do Not Display a Chondrocyte Phenotype
A130: Is the CCR5-delta32 Mutation Protective Against Systemic-Onset Juvenile Idiopathic Arthritis?
A131: Associations of Short–Term Pollution Exposures With Childhood Autoimmune Disease
A132: Farber Disease Explains Subset of Juvenile Idiopathic Arthritis
A133: Initial Benchmarking of the Quality of Medical Care of Children and Adolescents with Lupus
A134: Validation of Patient Reported Outomes Measurement Information System Modules for use in Childhood-;onset Lupus
A135: Final Year Undergraduate Medical Student Use and Acceptability of an e-Learning Module in Pediatric Rheumatology
A136: Assessing the Efficacy of Pediatric Rheumatology Video-based Curriculum
A137: Appropriateness of Rheumatology Lab Studies and Referrals among General Pediatricians
A138: Clinical Decision Support to Improve Preventive Care in Pediatric Systemic Lupus Erythematosus
A139: Body Mass Index and Height Change Over Time in Childhood-Onset Systemic Lupus Erythematosus Cohort
A140: Pediatric Rheumatology Admissions in Chile, 2001–2010: Unavailability of a Pediatric Rheumatologist May Hinder a Correct Diagnosis
A141: Active Engagement of Teens with Juvenile Idiopathic Arthritis in Medical Education: What Do They Think Their Contribution Might Be?
A142: Implementation of a Quality Improvement Initiative to Reduce Unintended Fetal Exposure to Teratogenic Medications among Female Pediatric Rheumatology Patients
A143: Barriers to Referral to Pediatric Rheumatology among General Pediatricians in the Upper Midwest
A144: Resident's Guide to Rheumatology Guide Mobile Application: An International Needs Assessment
A145: Faculty and Resident Perceptions About Teaching and Learning the Pediatric Musculoskeletal Examination: An Exploratory Study
A146: Strategies for Assessment and Management of Severe Environmental Allergies at “Camp JRA”
A147: Engaging Patients and Families in the Pediatric Rheumatology Care and Outcomes Improvement Network
A148: A Multi-Center, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab in Pediatric Patients With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy: Week 48 Results
A149: Does Prenatal Exposure to Antimalarial Decrease the Risk of Neonatal Lupus: a Bayesian Perspective
A150: Control of Cell Proliferation in Lupus Nephritis: The Role of miRNAs and HER2
A151: Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Performance Improvement on Juvenile Idiopathic Arthritis Quality Measures
A152: Safety and Effectiveness of Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis Aged 2 to 4 Years
A153: Long-term Outcomes of Childhood-Onset Systemic Lupus Erythematosus in Adulthood
A154: Glucocorticoid Therapy and the Risk of Incident Vertebral Fracture in Children with Rheumatic Disorders
A155: Development of an Intensive Interdisciplinary Pediatric Pain Rehabilitation Program: Improving Pain, Functioning, and Psychological Outcomes
A156: Pharmacokinetics and Pharmacogenetics of Mycophenolic Acid and Response to Therapy in Childhood-Onset Systemic Lupus Erythematosus
A157: Macrophage Activation Syndrome-like Illness Due to an Activating Mutation in NLRC4
A158: CpG-Induced Macrophage Activation Syndrome Develops Through an Organism Level Resistance to Toll-like Receptor 9 Tolerance
A159: The Autoimmune Genetic Architecture of Childhood Onset Rheumatoid Arthritis
A160: Role of Interleukin-1 in Abnormal Monocyte Phenotype in Systemic Onset Juvenile Idiopathic Arthritis
A161: Novel 3-Dimensional Explant Method Facilitates the Study of Lymphocyte Populations in the Synovium and Reveals a Large Population of Resident Memory T cells in Rheumatoid Arthritis
A162: Pre-visit Planning and Quality Improvement in Juvenile Idiopathic Arthritis
A163: Alternative Mechanisms of Care Delivery in Pediatric Rheumatology: To What Extent Do They Expand the Reach of Pediatric Rheumatologists?
A164: Development of Pediatric Item Banks to Measure Pain Behavior in the Patient Reported Outcomes Measurement Information System
A165: Implementing a Risk Education Strategy for Adolescent Girls Treated with Teratogenic Medications in the Pediatric Rheumatology Clinic
A166: Evaluation of Quality Indicators and Disease Damage in Childhood-Onset Systemic Lupus Erythematosus Patients
A167: Variations in Patterns of Care Across Pediatric Rheumatic Diseases in the Childhood Arthritis & Rheumatology Alliance Network Registry
A168: Systemic Lupus Erythematosus In-Hospital Mortality Risk Across Ages: A National Estimate
A169: Cumulative Long-Term Safety, Efficacy and Patient-Reported Outcomes in Children With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept: Up to 7 Years of Treatment
A170: Neoplasms in Pediatric Patients with Rheumatic Diseases Exposed to Biologics—A Quarternary Centre's Experience
A171: Tocilizumab Dosing in Juvenile Idiopathic Arthritis: Optimizing for Different Juvenile Idiopathic Arthritis Type and Patient Body Weight
A172: Metaphyseal Chondrodysplasia, Ectodermal Dysplasia, Short Stature, Hypergammaglobulinemia, and Spontaneous Inflammation Without Infections in an Extended Family Due to Mutation in NFKB1A
A173: Cerebrospinal Fluid Cytokines Correlate With Innate Immune Cells in Neonatal Onset Multisystem Inflammatory Disease (NOMID) Patients in Clinical Remission Treated With Anakinra
A174: JIA-Associated SNPs From Non-Coding Regions Are Located Within or Adjacent to Functional Genomic Elements of Human Neutrophils
A175: Dysbiosis of the Enteric Microbiota in Pediatric Spondyloarthritis
A176: Deep Sequencing Reveals Differential Small RNA Expression in Serum Exosomes of Children With Juvenile Idiopathic Arthritis
A177: Program Evaluation of the ACR/CARRA Inter-Institutional Mentoring Program (AMIGO) in Pediatric Rheumatology
A178: Development of Tools to Facilitate Shared Decision Making about Medications for Juvenile Idiopathic Arthritis—A Project of the Pediatric Rheumatology Care and Outcomes Improvement Network
A179: Improving Pneumococcal Vaccination Rate in the Pediatric Rheumatology Clinic
A180: A Population Management Tool for Proactive Care of Juvenile Idiopathic Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network
A181: Evaluating Decision-Making in a Pediatric Rheumatology Clinic